Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

Eli Lilly (LLY) stock in focus as the company's neuroscience chief Anne White retires, and the firm begins an executive ...

Eli Lilly's top neuroscience executive, Anne White, is retiring after three decades with the drugmaker. Eli Lilly on Wednesday said White will remain in her post as executive vice president and ...

Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience ...

Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with ...

Eli Lilly shares plunged about 14% in midday trading Thursday after the company reported less-than-stellar results of a new study of an experimental anti-obesity pill that is expected to become a ...

Pill Causes Major Weight Loss in Eli Lilly Trial’s Results The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the year.

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall Street.

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene editing treatments for high-risk patients.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.

Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with fewer side effects.

Key Points Visa, Netflix and Eli Lilly are moving closer to the trillion dollar club. While all three have the potential, one will reach $3 trillion sooner than the others.